Med策 Technology Secures Tens of Millions in Angel Funding to Reshape In Vitro Diagnostics with AI

VCBeat has learned that Hangzhou Yice Technology Co., Ltd. (hereinafter referred to as “Yice Technology”) recently announced the completion of its angel financing round, raising tens of millions of yuan. The round was led by Taikun Fund, with Deshi Capital participating as a co-investor. The funds will be primarily used for the R&D and regulatory registration of Yice Technology’s AI-based medical devices and digital platform applications, accelerate the deployment of its national marketing network across China, and expand into overseas markets.

PathoAI, founded in 2021, is a healthcare big data and artificial intelligence company centered on smart pathology and laboratory medicine. PathoAI focuses on the research, development, and clinical application of AI-powered products and comprehensive solutions for in vitro diagnostics, providing physicians with efficient and precise diagnostic and research support. Currently, PathoAI has established a “dual-engine” product pipeline strategy, integrating AI-based medical devices with smart cloud platform applications.

Over the two years since its establishment, PathoAI has achieved key progress and breakthroughs in multiple areas, including the development of AI-assisted diagnostic products and the construction of a digital platform for smart pathology.

The company has consistently adhered to medical diagnostics as its core driving force. Its first AI-assisted diagnostic product for cervical cytology, PathoInsight-T, was officially approved and launched in January 2022. This achievement realized a fully proprietary, closed-loop coverage of standardized overall solutions in the field of cervical cancer cytological screening, encompassing reagents and consumables, slide preparation and staining, digital scanning, and AI-based interpretation. It provides the market with truly implementable and efficiently operating AI-assisted diagnostic products for cervical cancer screening, along with end-to-end screening solutions. The company’s independently developed medical device image processing software products (including those for PD-L1, Ki67, etc.), as well as its digital systems and platforms (including the Smart Pathology Remote Consultation Platform, Microscope Online Interaction System, and Digital Pathology Storage Management System), have successively obtained domestic and international medical device certifications and been launched on the market. These offerings provide healthcare institutions with more reliable and diverse product options for establishing digital and intelligent pathology diagnostic platforms, thereby forming a comprehensive engine for digital and intelligent pathology services.

The company took the lead in formulating the “Data Standard System for the Standard Database of Cervical Cytology Images,” and released related outcomes on the AI Medical Device Innovation Cooperation Platform under the National Medical Products Administration (NMPA). This initiative aims to establish a scientific, comprehensive, high-quality, and expert-endorsed set of industry standards and specifications for the digitalization and intelligent analysis of cervical cytology images, thereby leveraging its own capabilities to take a solid step forward in advancing the standardization of pathology artificial intelligence in China.

Ms. Wang Xiaomei, CEO of PathoAIIt is stated that a successful AI-based medical device company must integrate multidimensional resources from both the medical and artificial intelligence fields, implement the development strategy of “medical-engineering integration,” and, on this basis, center on the deep convergence of “industry + technology + data” to empower the entire product design, original research, and market application. This constitutes the core lifeline for the translation of product achievements in AI medical device companies.

Mr. Sun Jun, Executive Director of Taikun FundIt was stated that, as a key vehicle for Dian Diagnostics in advancing its “Digital Intelligence Strategy,” PathoAI possesses vast amounts of high-quality data resources within the industry. Leveraging a three-tier review mechanism, PathoAI ensures the rationality and compliance of its data, achieving data quality that meets the industry’s gold standard and further realizing the value of data assets. Built upon leading big data platforms, analytical modeling, and cloud technologies, PathoAI has emerged as a domestic leader in the fields of AI-based medical devices and smart cloud platforms. Meanwhile, numerous opportunities are also evident in the pharmaceutical sector, and we look forward to PathoAI’s artificial intelligence technologies soon contributing to the development of the pharmaceutical industry.

Mr. Guo Jia, Partner at Deshi CapitalPathoAI has assembled a highly professional team comprising top-tier talent from the global fields of medicine, data science, and artificial intelligence algorithms. This team empowers the entire product design and R&D process while demonstrating strong capabilities in commercial implementation. Since its inception, PathoAI has been dedicated to exploring how artificial intelligence technology can be better applied within the healthcare sector. To date, its products have been deployed across various business scenarios, including third-party medical institutions, hospitals, and government-led cervical and breast cancer screening programs. Looking ahead, PathoAI aims to leverage big data and AI technologies to develop more high-quality, accessible products that benefit the healthcare industry.

PathoAI will leverage this financing round as an opportunity to continue upholding its vision of “building China’s leading AI pathology brand” and further advancing its corporate mission of “halting disease through technology.” The company will accelerate the R&D of its AI-based medical devices and digital pathology product series, expedite the acquisition of medical device registrations, refine its AI algorithms, and accumulate high-quality data resources. By integrating its full product portfolio into clients’ clinical operations, PathoAI aims to empower the development of the healthcare industry through technological innovation.

Taikun Fund is a biomedical industry fund jointly established by Tigermed, Hangzhou Capital, and Hangzhou High-Tech Innovation & Entrepreneurship. Leveraging Tigermed’s industrial layout as a clinical CRO and aligning with the development strategy of Hangzhou’s pharmaceutical industry, the fund operates on a market-oriented basis. Focusing on the life and health industry, it prioritizes investments in innovative medical devices, biopharmaceuticals, healthcare services, healthcare informatics, digital therapeutics, intelligent manufacturing, and nutritional health companies.

Deshi Capital is a specialized private equity investment management firm focused on investments in the pharmaceutical and healthcare sectors. Deshi Capital is committed to identifying investment opportunities in niche markets, collaborating with entrepreneurs and founders, and driving transformation in the pharmaceutical and healthcare industries.